Neoprobe Reports Revenues Of $2.7 Million In Q1 2009
The first quarter 2009 gross profit improvement represented an increase of 67% over the comparable period in 2008 and was due primarily to medical device sales. Operating expenses
Cellares and GenomeFrontier Therapeutics have announced a collaboration to assess automated manufacturing for the latter’s investigational CAR-T cell therapy, GF-CART01, on the Cell Shuttle platform.